Exact Mass: 439.2299874
Exact Mass Matches: 439.2299874
Found 142 metabolites which its exact mass value is equals to given mass value 439.2299874,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Leukotriene E4
C23H37NO5S (439.23923120000006)
Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4 activates contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways. Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)
Militarinone B
C26H33NO5 (439.23586080000007)
A natural product found in Isaria farinosa.
O-Desmethylvenlafaxine glucuronide
C22H33NO8 (439.22060580000004)
O-Desmethylvenlafaxine glucuronide is a metabolite of venlafaxine (brand name: Effexor or Efexor). Venlafaxine is a bicyclic antidepressant and is usually categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor. It works by blocking the transporter reuptake proteins for key neurotransmitters affecting mood, thereby leaving more active neurotransmitters in the synapse.
11-trans-LTE4
C23H37NO5S (439.23923120000006)
11-trans-LTE4 is also known as 11-trans-Leukotriene e4 or 11t-LTE4. 11-trans-LTE4 is considered to be practically insoluble (in water) and acidic. 11-trans-LTE4 is an eicosanoid lipid molecule
(5S,6R,7E,9E,11Z,14Z)-6-((R)-2-Amino-2-carboxyethylthio)-5-hydroxyicosa-7,9,11,14-tetraenoic acid
C23H37NO5S (439.23923120000006)
(S)-3-(6-Methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid
C23H29N5O4 (439.22194340000004)
Nvp-aew541
NVP-AEW541
Ala Gly His Arg
Ala Gly Arg His
Ala His Gly Arg
Ala His Arg Gly
Ala Arg Gly His
Ala Arg His Gly
Gly Ala His Arg
Gly Ala Arg His
Gly His Ala Arg
Gly His Arg Ala
Gly Arg Ala His
Gly Arg His Ala
His Ala Gly Arg
His Ala Arg Gly
His Gly Ala Arg
His Gly Arg Ala
His Arg Ala Gly
His Arg Gly Ala
Arg Ala Gly His
Arg Ala His Gly
Arg Gly Ala His
Arg Gly His Ala
Arg His Ala Gly
Arg His Gly Ala
11-trans-LTE4
C23H37NO5S (439.23923120000006)
A leukotriene that is the 11-trans-isomer of leukotriene E4.
14,15-Leukotriene E4
C23H37NO5S (439.23923120000006)
14,15-LTE4
C23H37NO5S (439.23923120000006)
Leukotriene E
C23H37NO5S (439.23923120000006)
A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).
Sulfamisterin
C19H37NO8S (439.22397620000004)
2-tert-Butyl-4-[3-(dimethylvinylsilanyl)propoxy]-6-(5-methoxybenzotriazol-2-yl)-phenol
{1-[2-Oxo-2-({4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}amino)ethyl]cyclopentyl}acetic acid hydrochloride (1:1)
C21H34ClN5O3 (439.2350044000001)
1,5-diphenyl-2-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]pyrazol-3-one
6-Amino-4-[3-ethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
C23H29N5O4 (439.22194340000004)
N-(2-phenylphenyl)-8-(4-pyridin-3-yltriazol-1-yl)octanamide
2-(3-ethoxypropylamino)-8-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[1,2-pyrimidinecarboxamide
C23H29N5O4 (439.22194340000004)
7-[3-(1-Azetidinylmethyl)cyclobutyl]-5-(4-phenylmethoxyphenyl)-4-pyrrolo[2,3-d]pyrimidinamine
(2s,3r)-2-Amino-(2-hydroxy-methyl)-12-oxo-3-(sulphooxy)octadecanoic acid
C19H37NO8S (439.22397620000004)
(2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(1R,9S,10S,11S)-N-(cyclopropylmethyl)-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-N-(cyclopropylmethyl)-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2S,3S,3aR,9bR)-1-ethyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
(2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
N,N-dimethyl-3-[4-[(1S,5R)-3-(1-oxo-2-phenylethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzamide
1-[(2S,3S)-1-[(4-fluorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(4-morpholinyl)ethanone
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylpyrazine-2-carboxamide
C23H29N5O4 (439.22194340000004)
(2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-1-ethyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
1-[(2S,3R)-1-[(4-fluorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(4-morpholinyl)ethanone
1-[(2R,3R)-1-[(4-fluorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(4-morpholinyl)ethanone
(2S)-N-{(2S)-1-[(3S)-3-carboxy-3,4-dihydroisoquinolin-2(1H)-yl]-1-oxopropan-2-yl}-1-ethoxy-1-oxo-4-phenylbutan-2-aminium
(1S,9R,10R,11R)-N-[(4-fluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-N-[(4-fluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-[(Z)-prop-1-enyl]-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] dodecanoate
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-heptanoyloxypropyl] heptanoate
(2-Hexanoyloxy-3-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(3-Acetyloxy-2-nonanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(2-Octanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] nonanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] octanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] undecanoate
(3-Butanoyloxy-2-heptanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] decanoate
eoxin E4
C23H37NO5S (439.23923120000006)
A leukotriene that is the 14R-(S-cysteinyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.
MePC(10:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
CP-868388 (free base)
C26H33NO5 (439.23586080000007)
CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions[1].
Denifanstat
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research[1][2].
9-ethyl-4,9-dihydroxy-8-methyl-4-(sec-butyl)-2,7,11-trioxa-16-azatricyclo[11.5.1.0¹⁶,¹⁹]nonadec-13-ene-3,6,10-trione
C22H33NO8 (439.22060580000004)
(1s,10s,11r,13s,14s,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C26H33NO5 (439.23586080000007)
3'-acetylheliosupine
C22H33NO8 (439.22060580000004)
{"Ingredient_id": "HBIN007878","Ingredient_name": "3'-acetylheliosupine","Alias": "NA","Ingredient_formula": "C22H33NO8","Ingredient_Smile": "CC=C(C)C(=O)OC1CCN2C1C(=CC2)COC(=O)C(C(C)OC(=O)C)(C(C)(C)O)O","Ingredient_weight": "439.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "37193","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "6431047","DrugBank_id": "NA"}
14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-yl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C26H33NO5 (439.23586080000007)
(1r,4s,8r,9s,19r)-4-[(2s)-butan-2-yl]-9-ethyl-4,9-dihydroxy-8-methyl-2,7,11-trioxa-16-azatricyclo[11.5.1.0¹⁶,¹⁹]nonadec-13-ene-3,6,10-trione
C22H33NO8 (439.22060580000004)
5-hydroxy-2-[hydroxy(4-hydroxyphenyl)methyl]-4-[(2e,4e,6e,8r,10r)-6,8,10-trimethyldodeca-2,4,6-trienoyl]-1,2-dihydropyrrol-3-one
C26H33NO5 (439.23586080000007)
(1s,7as)-7-({[(2s)-2-[(1s)-1-(acetyloxy)ethyl]-2,3-dihydroxy-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
C22H33NO8 (439.22060580000004)
(2s,4z)-5-hydroxy-2-[(s)-hydroxy(4-hydroxyphenyl)methyl]-4-[(2e,4e,6e,8r,10r)-1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene]-2h-pyrrol-3-one
C26H33NO5 (439.23586080000007)
(1s,7ar)-7-({[(2r)-2-[(1s)-1-(acetyloxy)ethyl]-2,3-dihydroxy-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
C22H33NO8 (439.22060580000004)
5-hydroxy-2-[hydroxy(4-hydroxyphenyl)methyl]-4-(1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene)-2h-pyrrol-3-one
C26H33NO5 (439.23586080000007)
(1r,2r,3s,4r,4ar,8ar)-2-hydroxy-3,4,8,8a-tetramethyl-4-[2-(5-oxo-2h-furan-3-yl)ethyl]-1,2,3,4a,5,6-hexahydronaphthalen-1-yl pyridine-3-carboxylate
C26H33NO5 (439.23586080000007)
(4z)-5-hydroxy-2-[hydroxy(4-hydroxyphenyl)methyl]-4-[(2e,4e,6e,8r,10r)-1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene]-2h-pyrrol-3-one
C26H33NO5 (439.23586080000007)
7-{[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-5-(acetyloxy)-1,3-benzoxazol-6-yl acetate
C26H33NO5 (439.23586080000007)
(1s,10s,11r,13s,14r,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C26H33NO5 (439.23586080000007)
(1r)-7-({[3-(acetyloxy)-2-hydroxy-2-(2-hydroxypropan-2-yl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
C22H33NO8 (439.22060580000004)
7-({[3-(acetyloxy)-2-hydroxy-2-(2-hydroxypropan-2-yl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2-methylbut-2-enoate
C22H33NO8 (439.22060580000004)
(2r,4z)-5-hydroxy-2-[(r)-hydroxy(4-hydroxyphenyl)methyl]-4-[(2e,4e,6e,8r,10r)-1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene]-2h-pyrrol-3-one
C26H33NO5 (439.23586080000007)